Clinical Trials Logo
  1. Home
  2. Type 2 Diabetes
  3. NCT03269058

Evaluate the Effects of Dapagliflozin in Patients With Type 2 Diabetes — Cinétique DAPA  

Type-2 Diabetes Clinical Trial

Official title:
Effects of Dapagliflozin on Lipoprotein Kinetics in Patients With Type 2 Diabetes

Clinical Trial Summary

This study will make it possible to better understand the mechanisms responsible for the increase in bad cholesterol levels observed in patients with type 2 diabetes treated with Dapagliflozin, an antidiabetic treatment made by Astrazeneca. The information will: - reveal what is not working properly - make it possible to choose the most appropriate treatments against cholesterol to compensate for this impaired functioning This biomedical research will take place at the University Hospitals of DIJON and NANTES. - 28 patients will take part: 20 patients will be given Dapagliflozin and 8 patients will be given the placebo. - The study treatment will be randomised: patients will be given either Dapagliflozin or the placebo. The treatment duration is 6 months. - Moreover, during the inclusion visit and at the end of the study (6 months after the start of treatment), a kinetics study, to follow the production and elimination of cholesterol, will be conducted. This will involve administering amino acids that have been specifically synthesised for this purpose. - Participation in the study will last 6 months and include 4 protocol visits.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03269058
Study type Interventional
Source Centre Hospitalier Universitaire Dijon
Contact
Status Completed
Phase Phase 4
Start date December 20, 2017
Completion date May 6, 2021
View Details
See also
  Status Clinical Trial Phase
Completed NCT02797392 - Feasibility of a Preventive Program Against Lifestyle Related Diseases N/A
Completed NCT01264523 - Nutritional Intervention With Moderately High-protein, Low-glycemic Load Products in Type-2 Diabetes Patients N/A
Completed NCT04105608 - GLP-1 and Oxyntomodulin Release in Relation to Diet in Type 2 Diabetes Patients. N/A
Completed NCT03624803 - DAPA - Egypt Study
Terminated NCT01787214 - Walnuts and Glucose Variability N/A
Completed NCT01715428 - Liraglutide and Cardio-Metabolic Risk Markers N/A
Completed NCT01884714 - Exploring the Molecular Basis to Healthy Obesity: The Diabetes Risk Assessment Study N/A
Completed NCT00567047 - Pharmacokinetic Study of Vildagliptin in Patients With Renal Impairment Phase 1
Completed NCT02191644 - Dietary Intervention Replacing Carbohydrate With Protein and Fat Has Greater Effect on Peripheral Blood Mononuclear Cell Metabolites Than on Plasma Metabolites in Patients With Prediabetes or Type-2 Diabetes Phase 2
Completed NCT01440660 - Phenotypes of Nonproliferative Diabetic Retinopathy in DM 2 Patients Identified by OCT, CFP, RLA and mfERG (DIAMARKER) N/A
Completed NCT01343589 - Effects of Milk Derived From Mountain-pasture Grazing Cows on Risk Markers of the Metabolic Syndrome Compared to Conventional Danish Milk N/A
Completed NCT00651105 - Effect of LAF237 on Glucagon Secretion in Patients With Type 2 Diabetes and in Healthy Subjects Phase 3
Completed NCT04330911 - The Effects of Aerobic Exercises on Exercise Capacity in Type-2 Diabetes Mellitus N/A
Completed NCT04952948 - Pilates Method on Functional Capacity and Blood Pressure of Elderly Women With Type 2 Diabetes N/A
Completed NCT00478127 - Hepatocyte Growth Factor and Cardiovascular Autonomic Function N/A